f755bd47-f8ff-4847-9b8e-7d36b7b84155
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 78
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- G2M_CHECKPOINT+0.380
- MYC_TARGETS_V2+0.360
- E2F_TARGETS+0.330
- WNT_BETA_CATENIN_SIGNALING+0.320
- PANCREAS_BETA_CELLS+0.300
- HEDGEHOG_SIGNALING+0.270
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.200
- MITOTIC_SPINDLE+0.180
- MYC_TARGETS_V1+0.150
- ANGIOGENESIS+0.110
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.440
- IL6_JAK_STAT3_SIGNALING-0.430
- INFLAMMATORY_RESPONSE-0.400
- COMPLEMENT-0.360
- FATTY_ACID_METABOLISM-0.340
- OXIDATIVE_PHOSPHORYLATION-0.340
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.310
- ADIPOGENESIS-0.300
- IL2_STAT5_SIGNALING-0.300
- APOPTOSIS-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR4296090 | — | cohortMD1 | 0.859 |
| 2 | TCGA-63-A5MW-01A-11R-A26W-07 | — | cohortMD1 | 0.830 |
| 3 | BS_NB42PWZN | EPN | Supratentorial EPN | 0.821 |
| 4 | s0095110 | — | — | 0.818 |
| 5 | b985822b-8c9c-4e26-9f11-4f5dbe736518 | — | — | 0.817 |
| 6 | TCGA-18-4083-01A-01R-1100-07 | — | cohortSQ2 | 0.814 |
| 7 | BS_44A3ES23 | medulloblastoma | — | 0.811 |
| 8 | TCGA-WA-A7GZ-01A-11R-A34R-07 | — | — | 0.810 |
| 9 | ad30e5e1-182b-4758-8e70-53e0bcf78072 | — | — | 0.805 |
| 10 | TCGA-AC-A5XU-01A-11R-A28M-07 | — | B | 0.804 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| G2M_CHECKPOINT | 0.380 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.360 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.330 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.320 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.300 | Cobimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.270 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.200 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.180 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.150 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.110 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.110 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.100 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.100 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.080 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.050 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.050 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.020 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.020 | Inavolisib | — uncovered |